EF5 to Evaluate Tumor Hypoxia in Patients With High-Grade Soft Tissue Sarcoma or Mouth Cancer
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This laboratory study is using EF5 to evaluate tumor hypoxia in patients with high-grade soft
tissue sarcoma or mouth cancer. Using the drug EF5 to measure the oxygen level in tumor cells
may help in planning cancer treatment